Organon Pharma Indonesia Tbk. vs Semen Baturaja Tbk. — how do they compare? Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B), while Semen Baturaja Tbk. trades at Rp172 (market cap 1.74T, 5.09M 24h volume). The key difference: Semen Baturaja Tbk. is far larger — about 16.7× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| SCPI | SMBR | |
|---|---|---|
Market Cap | 104.4B | 1.74T |
Volume | — | 5.09M |
Lot | — | 50.91K |
Turnover | — | 871.41M |
Average Price | — | 171.16 |
Value | — | 871.41M |
Indicative Equilibrium Price | — | 172 |
Indicative Equilibrium Volume | — | 150 |
Trailing returns across standard periods
Latest headlines on both assets
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →PT Semen Baturaja (Persero) Tbk (the Company) was established by Deed of Notary Jony Frederik Berthold Tumbelaka Sinjai No. 34, in Jakarta, dated November 14, 1974, amended by the same notary on November 21, 1974, amended by the same notary on November 21, 1974 Deed No. 49.
Read more on SMBR →